# Inhaled Ciclesonide for Outpatients With COVID19

> **NCT04435795** · PHASE2,PHASE3 · TERMINATED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 215 (actual)

## Conditions studied

- COVID 19

## Interventions

- **DRUG:** Normal Saline intranasal and placebo inhaler
- **DRUG:** Ciclesonide
- **DRUG:** Ciclesonide nasal

## Key facts

- **NCT ID:** NCT04435795
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-15
- **Primary completion:** 2021-06-08
- **Final completion:** 2021-07-08
- **Target enrollment:** 215 (ACTUAL)
- **Why stopped:** could not meet target enrolment
- **Last updated:** 2022-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04435795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04435795, "Inhaled Ciclesonide for Outpatients With COVID19". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04435795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*